Structures by: Nagl A.
Total: 11
Dibenz[c,e]azepine
C17H19N
Acta Crystallographica Section C (1998) 54, 6 877-879
a=9.1680(10)Å b=9.313(3)Å c=16.590(9)Å
α=90.00° β=105.88(2)° γ=90.00°
Furylbenzothiazol
C18H10N2OS2
Acta Crystallographica Section C (1996) 52, 10 2541-2543
a=20.753(7)Å b=4.017(1)Å c=17.476(3)Å
α=90.° β=93.25(2)° γ=90.°
Bis(2-acetylamino-1,3,5-thiadiazole-2-sulfon)amide Dihydrate
C8H9N7O6S4,2H2O
Acta Crystallographica Section C (1994) 50, 7 1099-1101
a=16.045(7)Å b=11.868(4)Å c=9.828(5)Å
α=90° β=104.74(2)° γ=90°
7-hydroxy-3-methoxy-4-methyl-5,6,7,8-tetrahydropyrido[1,2-c]pyrimidin- 1(8aH)-one
C10H14N2O3
Acta Crystallographica Section C (2005) 61, 3 o158-o160
a=9.955(4)Å b=6.9722(12)Å c=14.673(4)Å
α=90.00° β=90.00° γ=90.00°
N-(o-chlorophenyl)-2,5-dimethylpyrrole-3-carbaldehyde
C13H12ClNO
Acta Crystallographica Section C (2003) 59, 7 o357-o359
a=21.6815(3)Å b=8.61270(10)Å c=19.7231(2)Å
α=90.00° β=101.6257(5)° γ=90.00°
(E)-1-[4-(N-Phthalimido)-2-butenyl]uracil
C16H13N3O4
Crystal Growth & Design (2008) 8, 8 2975
a=10.1870(2)Å b=13.4049(3)Å c=10.6494(2)Å
α=90.00° β=92.792(2)° γ=90.00°
(E)-1-[4-(N-Phthalimido)-2-butenyl]-5-fluorouracil
C16H12FN3O4
Crystal Growth & Design (2008) 8, 8 2975
a=9.4250(4)Å b=9.7967(4)Å c=10.3001(3)Å
α=63.852(4)° β=68.655(3)° γ=63.734(4)°
(E)-1-[4-(N-Phthalimido)-2-butenyl]-5-(trifluoromethyl)uracil
C17H12F3N3O4
Crystal Growth & Design (2008) 8, 8 2975
a=27.2485(6)Å b=6.8993(2)Å c=18.0188(5)Å
α=90.00° β=96.858(2)° γ=90.00°
(Z)-1-[4-(N-Phthalimido)-2-butenyl]-5-fluorouracil
C16H12FN3O4
Crystal Growth & Design (2008) 8, 8 2975
a=9.8863(6)Å b=10.3331(6)Å c=16.5554(9)Å
α=77.454(5)° β=83.765(5)° γ=61.683(6)°
Pb4 Sb21 Tl8 As19 S68
As19Pb4S68Sb21Tl8
Zeitschrift fuer Kristallographie (149,1979-) (1979) 150, 85-106
a=16.32Å b=42.636Å c=8.543Å
α=83.98° β=89.06° γ=83.2°
Chabourneite
As19Pb4S68Sb21Tl8
Zeitschrift fur Kristallographie (1979) 150, 85-106
a=16.320Å b=21.3180Å c=8.543Å
α=83.98° β=89.06° γ=83.20°